Segall Bryant & Hamill LLC Has $10.02 Million Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Segall Bryant & Hamill LLC lowered its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 50.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 30,024 shares of the company's stock after selling 30,888 shares during the quarter. Segall Bryant & Hamill LLC owned 0.10% of Medpace worth $10,022,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Ashton Thomas Securities LLC acquired a new position in shares of Medpace in the third quarter valued at approximately $37,000. DT Investment Partners LLC acquired a new position in shares of Medpace in the second quarter valued at approximately $41,000. Capital Performance Advisors LLP acquired a new position in shares of Medpace in the third quarter valued at approximately $46,000. Ashton Thomas Private Wealth LLC acquired a new position in shares of Medpace in the second quarter valued at approximately $52,000. Finally, EntryPoint Capital LLC acquired a new position in shares of Medpace in the first quarter valued at approximately $54,000. Institutional investors and hedge funds own 77.98% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on MEDP. StockNews.com lowered shares of Medpace from a "buy" rating to a "hold" rating in a research report on Friday, September 27th. TD Cowen cut their price objective on shares of Medpace from $413.00 to $372.00 and set a "buy" rating on the stock in a research report on Wednesday, October 23rd. Redburn Atlantic began coverage on shares of Medpace in a research report on Monday, October 14th. They issued a "buy" rating and a $404.00 price objective on the stock. Robert W. Baird lowered shares of Medpace from an "outperform" rating to a "neutral" rating and cut their price objective for the stock from $413.00 to $349.00 in a research report on Wednesday, October 23rd. Finally, Jefferies Financial Group lowered shares of Medpace from a "buy" rating to a "hold" rating and cut their price objective for the stock from $415.00 to $345.00 in a research report on Wednesday, September 25th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, Medpace currently has an average rating of "Hold" and an average target price of $380.00.

Medpace Price Performance

NASDAQ MEDP traded down $4.07 on Friday, hitting $337.75. 351,389 shares of the stock were exchanged, compared to its average volume of 285,250. The business's fifty day moving average is $340.42 and its 200 day moving average is $373.77. Medpace Holdings, Inc. has a 52 week low of $268.80 and a 52 week high of $459.77. The company has a market capitalization of $10.50 billion, a PE ratio of 30.32, a P/E/G ratio of 1.74 and a beta of 1.37.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.24. The company had revenue of $533.32 million for the quarter, compared to analyst estimates of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The company's revenue was up 8.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.22 earnings per share. Analysts predict that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.